Drug Profile

DXC 007

Alternative Names: DXC-007

Latest Information Update: 28 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hangzhou DAC Biotech
Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
Mechanism of Action Microtubule protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Aug 2025 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in China (Parenteral, Injection)
16 Feb 2023 National Medical Products Administration approves IND application for DXC 007 in Leukemia (Hangzhou DAC Biotech pipeline, February 2023)
16 Feb 2023 Hangzhou DAC Biotech plans a phase I trial for Leukemia (Hangzhou DAC Biotech pipeline, February 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com